Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Mark W Rixon

1PUBLICATIONS

6CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Apr 05, 2022

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

Mark F Maurer, Katherine E Lewis, Joseph L Kuijper

Pageof 1

Frequent Collaborators

1 joint publications

Mark F Maurer

1 joint publications

Stacey R Dillon

1 joint publications

Yengo Raymond Kimbung

1 joint publications

Derek T Logan

1 joint publications

Björn Walse

1 joint publications

Stanford L Peng

Frequent Collaborators

1 joint publications

Mark F Maurer

1 joint publications

Stacey R Dillon

1 joint publications

Yengo Raymond Kimbung

1 joint publications

Derek T Logan

Top Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on : Jan 07, 2019

See more related videos

Top Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on : Jan 07, 2019

See more related videos